PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Study to Learn How Different Tablets of the Study Medicine Vepdegestrant Are Taken up Into the Blood in Healthy Adults

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: single dose of vepdegestrant as tablet formulation (Treatment A)
Drug: single dose of vepdegestrant as tablet formulation (Treatment B)

First Posted Date: 2024-10-17

Last Posted Date: 2025-05-25

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT06645938

Locations: 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium

A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

Phase 3

Recruiting

Conditions: Menstrual Migraine

Interventions: Drug: Rimegepant
Drug: Placebo Comparator
Drug: Standard of Care

First Posted Date: 2024-10-15

Last Posted Date: 2025-05-31

Lead Sponsor: Pfizer

Target Recruit Count: 723

Registration Number: NCT06641466

Locations: 🇺🇸
Clinvest Headlands Llc, Springfield, Missouri, United States
🇺🇸
Velocity Clinical Research, Providence, East Greenwich, Rhode Island, United States
🇨🇦
OCT Research ULC, Kelowna, British Columbia, Canada

and more 27 locations

Patient Interview Study to Explore the Impact of Gene Therapy in Hemophilia A & B

Not yet recruiting

Conditions: Hemophilia A
Hemophilia B

First Posted Date: 2024-10-10

Last Posted Date: 2025-03-05

Lead Sponsor: Pfizer

Target Recruit Count: 40

Registration Number: NCT06634836

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

Phase 3

Recruiting

Conditions: Metastatic Castration-Resistant Prostate Cancer

Interventions: Drug: PF-06821497
Drug: Placebo
Drug: Enzalutamide

First Posted Date: 2024-10-08

Last Posted Date: 2025-06-06

Lead Sponsor: Pfizer

Target Recruit Count: 900

Registration Number: NCT06629779

Locations: 🇺🇸
Ironwood Cancer & Research Centers, Scottsdale, Arizona, United States
🇺🇸
Palo Verde Hematology Oncology, Glendale, Arizona, United States
🇺🇸
Arizona Urology Specialists (East Side Location), Tucson, Arizona, United States

and more 165 locations

A Study to Learn About How Medicines Called CDK4/6 Inhibitors Are Used in People With Advanced or Metastatic Breast Cancer in Australia

Completed

Conditions: Breast Neoplasms

First Posted Date: 2024-10-02

Last Posted Date: 2024-10-02

Lead Sponsor: Pfizer

Target Recruit Count: 1128

Registration Number: NCT06624020

Locations: 🇦🇺
Pfizer Australia, Sydney, New South Wales, Australia

A Study to Learn About the Safety of PREVENAR 20 Vaccine in Infants Aged Between Two to Six Months

Active, not recruiting

Conditions: Pneumococcal Disease

Interventions: Biological: 20-valent Pneumococcal Conjugate Vaccine

First Posted Date: 2024-10-01

Last Posted Date: 2025-05-06

Lead Sponsor: Pfizer

Target Recruit Count: 1100

Registration Number: NCT06622109

Locations: 🇯🇵
Pfizer, Tokyo, Japan

A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine

Phase 3

Recruiting

Conditions: Migraine

Interventions: Drug: Rimegepant
Drug: Placebo

First Posted Date: 2024-09-27

Last Posted Date: 2025-06-06

Lead Sponsor: Pfizer

Target Recruit Count: 200

Registration Number: NCT06616194

Locations: 🇪🇸
CHUVI- Hospital Alvaro Cunqueiro, Vigo, Pontevedra, Spain
🇪🇸
Hospital Universitario HM Sanchinarro, Madrid, Spain
🇪🇸
Hospital Universitario Virgen Del Rocio, Sevilla, Spain

and more 60 locations

Korean Post Marketing Surveillance for Comirnaty Injection (Bretovameran)

Active, not recruiting

Conditions: COVID-19 Vaccination

Interventions: Biological: Bretovameran

First Posted Date: 2024-09-26

Last Posted Date: 2025-05-31

Lead Sponsor: Pfizer

Target Recruit Count: 660

Registration Number: NCT06613984

Locations: 🇰🇷
Pfizer Korea, Seoul, Korea, Republic of

A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared With Standard of Care Therapies

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Elranatamab
Drug: Standard of care

First Posted Date: 2024-09-19

Last Posted Date: 2025-05-20

Lead Sponsor: Pfizer

Target Recruit Count: 4

Registration Number: NCT06592222

Locations: 🇺🇸
Pfizer, New York, New York, United States

A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Older Adults in Korea

Phase 3

Completed

Conditions: Respiratory Syncytial Virus

Interventions: Biological: RSVpreF Vaccine
Other: Placebo

First Posted Date: 2024-09-19

Last Posted Date: 2025-02-14

Lead Sponsor: Pfizer

Target Recruit Count: 377

Registration Number: NCT06593587

Locations: 🇰🇷
Inha University Hospital, Incheon, Incheon-gwangyeoksi [incheon], Korea, Republic of
🇰🇷
Jeonbuk National University Hospital, Jeonju-si, Jeonrabugdo, Korea, Republic of
🇰🇷
Chonnam National University Hospital, Gwangju-si, Kwangju-kwangyǒkshi, Korea, Republic of

and more 13 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy